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Background: High dietary fiber intake has been associated with reduced risk of
Helicobacter pylori infection and co-morbidities such as gastric cancer but also with
reduced risk of cardiovascular disease. It has been suggested that fermented rye could
affect Helicobacter pylori bacterial load and that high- fiber rye may be superior to wheat
for improvement of several cardiometabolic risk factors, but few long-term interventions
with high fiber rye foods have been conducted.
Objective: To examine the effect of high-fiber wholegrain rye foods with added
fermented rye bran vs. refined wheat onHelicobacter pylori infection and cardiometabolic
risk markers in a Chinese population with a low habitual consumption of high fiber
cereal foods.
Design: A parallel dietary intervention was set up and 182 normal- or overweight men
and women were randomized to consume wholegrain rye products containing fermented
rye bran (FRB) or refined wheat (RW) for 12 weeks. Anthropometric measurements,
fasting blood sample collection and 13C-urea breath test (13C-UBT) were performed at
baseline and after 6 and 12 weeks of intervention as well as 12 weeks after the end of
the intervention.
Results: No difference between diets on Helicobacter pylori bacterial load measured
by 13C-UBT breath test or in virulence factors of Helicobacter pylori in blood samples
were found. Low density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive
protein (hs-CRP) were significantly lower in the FRB group, compared to the RW group
after 12 weeks of intervention. The intervention diets did not affect markers of glucose
metabolism or insulin sensitivity.
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Conclusions: While the results of the present study did not support any effect of FRB on
Helicobacter pylori bacterial load, beneficial effects on LDL-C and hs-CRP were clearly
shown. This suggest that consumption of high fiber rye foods instead of refined wheat
could be one strategy for primary prevention of cardiovascular disease.
Clinical Trial Registration: The trial was registered at www.clinicaltrials.gov,
Identifier: NCT03103386.
Keywords: wholegrain, rye, cardiovascular disease,Helicobacter pylori, inflammation, LDL cholesterol, C-reactive
protein, cereal fiber
INTRODUCTION
Helicobacter pylori (H. pylori) is a common pathogen infecting
approximately half the world’s population (1). In China, the
prevalence has been estimated to 56% but may differ substantially
between regions (1). Epidemiological and clinical studies show
thatH. pylori infections lead to increased risk for several diseases
including superficial gastritis, gastric and duodenal ulcers and
gastric cancer (2–5). A growing number of experiments including
in vitro and animal studies, as well as clinical trials have revealed
the definite role of H. pylori in gastric carcinogenesis (6). H.
pylori has been identified as a Group I carcinogen by the
International Agency for Research on Cancer and is currently
recognized as a major cause of gastric adenocarcinoma (7, 8).
It has been estimated that about 78% of all gastric cancers can
be attributable to H. pylori infection (9). Studies proposed that
dietary patterns may play a crucial role in defining the final
outcome of a H. pylori infection and diet may play an interactive
role with H. pylori for development of gastric cancer (6, 10, 11).
Probiotics, in the form of yogurts and supplements has shown a
modest potential for H. pylori eradication (12). However, further
clinical trials are required for improved understanding of the
role of specific dietary components in H. pylori pathogenesis
and development (13). Direct methods for investigating the
development and progression of diseases in the upper GI-tract
are typically invasive and are therefore difficult to use in a wide
context (14, 15). Urea breath test (UBT) is a commonly used,
non-invasive diagnostic tool to measure presence or absence of
H. pylori infection. It measures the urease activity of H. pylori
in the stomach after intake of labeled urea and detects 13C
labeled CO2. It is a widely used diagnostic tool due to its high
accuracy and low impact on patients, as compared to invasive
methods such as endoscopic examinations of the gastrointestinal
tract (14, 15).
Cardiovascular disease (CVD) accounts for 30% of global
mortality and is the main cause of death overall with 17.3
million people dying from the disease every year (16). In China,
CVD accounts for 45 and 43% of all deaths in rural and
urban areas, respectively (17). Moreover, the prevalence of type
2 diabetes (T2D) is increasing rapidly all over the world. In
China, almost 10% of all adults have T2D (18). Results from
large cohort studies have clearly shown that healthy eating
and an active lifestyle are important aspects for prevention
and control of cardiometabolic diseases such as CVD and
T2D (19–22). Based on observational data, high wholegrains
and cereal fiber intakes have consistently been associated with
lower incidence and mortality from non-communicable diseases,
such as CVD and T2D (23–26). In addition to other well-
established mechanisms (27), wholegrains and/or cereal fiber
may have a favorable effect on local and systemic inflammatory
processes (28–31). Reduced inflammation has been associated
with lowered incidence and less adverse outcome in CVD
and T2D, and biomarkers such as high sensitivity C-reactive
protein (hs-CRP) and interleukin 6 have been forwarded
as independent risk markers of CVD (32–36). Due to its
higher fiber content, rye has been suggested to be superior
to other cereals in terms of improving metabolic risk markers
(37) with some supportive evidence from a few conducted
studies (38–40).
Based on positive findings from in vitro studies showing
reduced adherence and colonization of H. pylori in response
to supernatants from fermented rye bran and feasibility of
consuming fermented rye bran from a small pilot study in
humans (www.epo.org, patent no.: EP1450626), the aim of the
present study was to examine the effects of high-fiber wholegrain
rye foods with added fermented rye bran vs. refined wheat as a
strategy to reduce the H. pylori bacterial load among H. pylori
positivemen andwomen from aChinese population, in a 12 week
randomized controlled trial. We further investigated the effect of
the intervention on cardio-metabolic risk factors, as secondary
outcomes. We hypothesized that consumption of wholegrain rye
with fermented rye bran, compared with refined wheat, would
reduce H. pylori bacterial load and have a favorable effect on
cardio-metabolic risk factors.
METHODS
A 12-week randomized parallel intervention study was
conducted to compare the effects of wholegrain rye products
with added fermented rye bran (FRB) vs. refined wheat (RW)
products (control) on normal weight and overweight participants
with H. pylori infection. Participants who completed the study
were invited to participate in a follow up visit 12 weeks after
completing the intervention. The study was conducted at
Zhongye Hospital, Shanghai, in April-October 2015. Participants
gave written consent before each visit to the clinic, as well as oral
consent before each procedure. The study was approved by the
Institutional Review Board at Fudan University and the study
was conducted in accordance with the Declaration of Helsinki.
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Intervention Diets
The intervention diets consisted of four pieces of crisp bread and
two portion packs of extruded cereal puffs per day, providing
∼515 kcal/d (Table 1). Participants were free to consume the
products at any time of the day to facilitate compliance. Products
were packed in neutral packaging materials and participants
were not informed which diet they were allocated to, but
as wheat and rye products differ visually some participants
might have guessed their allocation. Hospital staff conducting
the outcome assessment were not aware of the participants’
treatment allocation.
The FRB products were produced from dried fermented rye
bran, incorporated into wholegrain rye crisp bread product and
extruded wholegrain rye puffs (25% on weight basis). The RW
products were refined wheat crisp bread and extruded refined
wheat puffs. The fermented rye bran (provided by Lantmännen,
Stockholm, Sweden) was prepared by mixing rye bran with
autoclaved tap water in a proportion of 1:5 w/w. Lactobacillus
plantarum (DSMZ 13890) was cultured at 37◦C for 24 h onMRS-
agar, and thereafter it was suspended in autoclaved tap water and
added in the rye bran-water mixture to final concentration of
105 bacteria/mL. The mixture was incubated at 37◦ under gentle
agitation for 24 h in 4 different batches. The final concentration
of L. plantarum in the fermented rye bran was estimated by count
of colony forming units to about 109/mL. The fermented rye bran
was dried and used in the production of products.
The crisp bread with fermented rye bran contained
wholegrain rye flour (7.5 kg), fermented rye bran (2.5 kg),
water (13.5 kg) and salt (100 g). The dough was mixed, baked
in the oven for 10min (gradient temperature) and dried for
30min at 80◦C, resulted in a final water content of 7%. The RW
crisp bread contained wheat flour (10 kg), dextrose (400 g) water
(3.6 kg), salt (133 g) and yeast (1.92 kg, 8% solution). The dough
was mixed, pre-warmed for 35min, baked in the oven for 7.5min
(gradient temperature) and dried for 30min at 80◦C, resulted in
a final water content of 7%.
Both FRB and RW puffs were extruded on a co-rotating twin
screw extruder APV MPF 19/25 (Baker Perkins Group Ltd.,
Peterborough, UK), with a screw speed of 450 rpm at 103◦C. The
feed rate of flour mixture was 50 g/min and water was added at a
rate of 2.5–6 ml/min. After extrusion the puffs were oven dried
for 45min at 100◦C. The flour mixture RW puffs consisted of
refined wheat flour (98.2% w/w), salt and ascorbic acid, whereas
the flour mixture for FRB puffs contained whole grain rye flour
(74.2% w/w), fermented rye bran (25% w/w) and salt.
Composition of Intervention Products
Samples of crisp bread and puffs were freeze dried and milled
with a cyclone sample mill (Retsch, Haan, Germany). Dietary
fiber content was analyzed according to the Uppsala method
(41). Fructan, and starch content were analyzed using a K-FRUC
kit (42), and a K-TSTA kit (43), respectively (Megazyme, Bray,
Ireland). Crude fat was determined according to the method
described in the Official Journal of the European Communities
(1984) and protein according to the Kjeldahl method (N × 6.25).
Dry matter was determined by drying the samples at 105◦C for
16 h according to the AACC method 44-15A.
Participants, Screening, and
Randomization
Males and females, aged 20–70 years old, were invited to
attend a screening visit at Zhongye Hospital. Participants were
screened for H. pylori infection with 13C-urea breath test
(13C-UBT), and as per manufacturer’s recommendation a delta-
over-baseline (DOB) value >4‰ were considered positive for
H. pylori infection. H. pylori negative participants, as well as
participants who reported smoking, use of medications (except
for mild hypertension medication), chronic disease such as
diabetes, CVDs or cancer, active peptic ulcers, pregnancy or
planning pregnancy within the duration of the study, allergies
or food intolerances or travel plans within coming 4 months
were excluded.
The aim was that 50% of participants recruited should have
BMI ≤ 24.00 (normal weight) and 50% should have BMI >
24.00 (overweight), as H. pylori infection has been shown to
be associated with BMI (44, 45). BMI of 24 kg/m2 was chosen
as cut-off as it has been shown to be the optimal distinction
between overweight and normal weight in an adult Chinese
population (46).
Eligible participants were randomly assigned to either the
FRB or RW diet (1:1) by the study investigators in Shanghai.
The randomization sequence was generated in Microsoft Excel



















Fermented rye bran (FRB)
Crisp bread 44.8 145.5 4.3 1.2 23.9 11.1 3.9 3.2 1.2
Puffs 110.0 372.6 11.4 3.3 61.2 26.3 3.5 5.0 2.8
Sum 154.8 518.1 15.7 4.5 85.1 37.4 7.4 8.2 4.0
Refined wheat (RW)
Crisp Bread 58.8 210.5 6.8 1.0 41.2 3.6 0.9 4.5 1.1
Puffs 84.0 302.7 9.7 1.6 58.1 8.6 4.0 4.9 1.4
Sum 142.8 513.2 16.4 2.6 99.3 12.2 4.9 9.4 2.3
aCalculated by difference. bFiber content as analyzed by the Uppsala method with inclusion of fructans. The bold rows are the summary rows.
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and stratified for weight status (overweight or normal weight)
to ensure equal distribution of normal weight and overweight
subjects in each group. Participants in the two weight groups
were ranked according to their 13C-UBT value obtained at the
screening visit and every other person were then allocated to
FRB or RW, respectively. Two participants chose to withdraw
from the study shortly after randomization, before baseline,
and two additional participants were chosen from the pool
of screened volunteers to increase the sample size. Those two
participants belonged to the same weight group and had 13C-
UBT values in the same range as the withdrawn participants and
were therefore allocated based on the withdrawn participants
place in the ranked lists (both were allocated to FRB). One of
these participants were however excluded at a later stage due
having consumed antibiotics during screening and therefore not
fulfilling the inclusion criteria. Furthermore, two participants,
one in each intervention group, were mistakenly provided wrong
foods at baseline andwere re-allocated to the diet groupmatching
the provided food.
Study Design, Procedures, and Sample
Size
Participants attended an examination visit at the clinic at
baseline, and after 6 and 12weeks of intervention. All participants
who completed the 12-week intervention were invited to attend
a follow-up visit 12 weeks after finalizing the intervention (24
weeks after baseline). Participants were instructed to avoid food
and beverages, with the exception of water, from 18:00 the day
before each examination.
At the examination, participants underwent anthropometric
measurements and bacterial load was estimated using 13C-UBT.
Blood samples were drawn into a 7ml EDTA tube and 7ml serum
tube, following a 5min rest in a supine position. EDTA tubes were
centrifuged immediately after sampling, whereas serum tubes
were kept at room temperature for 30min before centrifugation.
Samples were centrifuged 10min at 4◦C under 2,000 g and
aliquoted into serum, plasma, buffy coat and red blood cells. The
lipids, glucose, insulin and hs-CRP concentrations were analyzed
with the fresh blood by the clinical diagnostic center of Zhongye
Hospital. The remaining samplematerial was stored at−80◦C for
later analysis.
The primary outcome of the study was difference in
DOB between treatments. Based on previous pilot studies we
hypothesized that a 30% difference in DOB between treatments
after 12 weeks could have clinical relevance. In order to detect a
two-side difference between treatments of 30% using a σ = 919
(based on results from a pilot study), α = 0.05, with a statistical
power of 80%, 75 participants in each group would be required. A
drop-out rate of 20% was assumed and therefore 90 subjects per
treatment arm were recruited.
Anthropometric Measurements
At the screening visit, height was measured on a wall mounted
stadiometer (Stature meter 2m, Dongguan Nancheng Chengbida
Electronic Equipment Factory, China) with the participant not
wearing shoes. Body weight and body fat [determined by
bioelectrical impedance analysis (BIA)], were measured on an
electric scale [OMRON V-body HBF-701, OMRON Healthcare
(China) Co., Ltd., China] with participants wearing light clothing
and no shoes at baseline, week 6, 12 and 24.
A subgroup of 54 participants were selected on a volunteer
basis to undertake a dual energy x-ray absorptiometry (DEXA)
scan at all three occasions, in addition to the BIA, in order
to validate the accuracy of the BIA measurements. The DEXA
scan was conducted with a Lunar Prodigy Dual Energy X-
ray Absorptiometer (GE healthcare, Illinois, USA) at Shanghai
University of Sports under the same fasting conditions as
the examinations.
Urea Breath Test
A 13C-UBT (Helicobacter pylori tester SN 2 6918, Shenzhen
Zhongnuke Headway Biotechnology Co., Ltd., China) was used
as a non-invasive diagnostic tool to measure the presence of H.
pylori at screening as well as at examination visits. Participants
breathed into a gas collection bag before and 30min after
consuming a tablet containing 75mg 13C labeled urea along with
80–100ml of water. The carbon dioxide abundance in the exhaled
air was detected by the instrument and the difference between the
two time points were calculated and expressed as DOB in ‰. As
per the manufacturer’s recommendation, DOB values above 4‰
were set as the cut-off and interpreted as positive indicator of H.
pylori infection.
Biochemical Analysis
Plasma glucose, total cholesterol (TC), high density lipoprotein
cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-
C), triglycerides and Apolipoprotein A/B/E/(a) were measured
by a 7180 Clinical Analyzer (Hitachi, Japan). Serum hemoglobin
A1c was measured by the VARIANTTM II TURBO Hemoglobin
Testing System (Bio-Rad, USA). Serum insulin and C-peptide
were measured by immunoassay using Cobas E601 analyzer
(Roche, USA). Serum hs-CRP was measured with IMMAGE R©
800 immunochemistry system (BeckmanCoulter, USA). HOMA-
IR was calculated as follows: fasting glucose (mmol/L) ×
[fasting insulin (pmol/L)/6]/22.5 (47). Plasma alkylresorcinols
(AR) were analyzed by gas chromatography–mass spectrometry
as a measure of wholegrain and bran intake from rye and wheat
sources (48).
Antibodies directed against virulence factors were measured
in serum, as a supportive measure of the H. pylori infection
diagnosis made by 13C-UBT. Antibodies against the following
virulence factors were measured: cytotoxin-associated gene A
(anti-CagA), vacuolating cytotoxin A (anti-VacA), urease A
(anti-UreA) and urease B (anti-UreB). Analysis was conducted by
Western blot (Typing detection kit for antibody to Helicobacter
pylori, Shenzhen blot biotech Co., Ltd., China) according to the
instructions provided by the manufacturer.
Statistical Analysis
All statistical analyses followed a per-protocol approach inherent
to the design of the study. All outcomes, except serology, were
analyzed using an unadjusted ANOVA model (Model 1) and an
ANCOVA model (Model 2) adjusted for weight change (from
baseline to week 6 and baseline to week 12, respectively), age
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and sex. Analyses of body weight and fat percentage were not
adjusted for weight change. Models were visually inspected using
quantile-quantile-plots and residual plots and response variables
were log transformed if residuals were non-normally distributed.
Estimates are presented as mean ± standard deviation. Median
was used when estimates appeared skewed in a histogram.
Stratified analysis dividing participants into overweight and
overweight (status at baseline) was conducted by the same
procedure as the unstratified analyses.
McNemar’s test was used to evaluate the change in the number
of seropositive participants from baseline to weeks 6, 12, and
24, respectively.
Analyses of hs-CRP was conducted after excluding
observations ≥1 mg/L, as concentrations above this could
indicate an acute infection (e.g., influenza, common cold,
bacterial infections etc.) rather than low grade/chronic
inflammation related to metabolic status/risk. Hs-CRP
measures below the detection limit (<12.7% of the
observations) was imputed the value of the detection
limit (0.02 mg/L).
For the validation of BIA against DEXA pearson’s correlation
coefficient were calculated for each of the three occasions
(baseline, weeks 6 and 12).
All data presented in tables are unadjusted data. p-values
< 0.05 are considered statistically significant. Complete-case
analysis was defined as the primary analysis strategy. The
statistical analyses were carried out using R Studio (version 3.3.0
(2016-05-13), for Windows 7), and all estimates were derived
using the plyr-package (version 1.8.3). Figures were made with
GraphPad Prism 7 (version 7.04 (2017-11-28), for Windows 7).
RESULTS
In total, 569 men and women were screened by 13C-UBT to
determine whether they wereH. pylori positive or not (Figure 1).
In total, 316 participants (55%) were found to be H. pylori
positive (with DOB > 4‰). After exclusion of participants that
did not fulfill additional inclusion/exclusion criteria, 182H. pylori
positive participants, hereof 94 normal weight and 88 overweight,
FIGURE 1 | Flow sheet of participants.
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TABLE 2 | Baseline characteristics of the participants who completed the 12-week intervention.
Intervention groups













Age (years)a 44.5 ± 12.5 44.9 ± 11.8 44.1 ± 13.4 45.4 ± 14.0 48.9 ± 11.7 42.7 ± 15.1
BMI (kg/m2 )a 24.3 ± 3.9 27.2 ± 3.1 21.4 ± 1.8 24.1 ± 4.2 27.9 ± 3.2 21.1 ± 1.8
Female/male (n) 62/18 28/13 34/5 64/14 27/7 37/7
aValues expressed as mean and standard deviation. bBMI > 24 kg/m2. cBMI ≤ 24 kg/m2.
were included in the study and randomized to either FRB (n =
92) or RW (n= 90).
Among 92 participants randomized in the FRB, 81
participants (88%) completed the 12-week intervention. The
corresponding figure for the RW was 80 out of 90 randomized
participants that completed the study (89%). The reasons for
dropout were similar in both groups and included illness,
travels, difficulties to adhere to the diet, use of antibiotics and
treatment against H. pylori infection (Figure 1). Additionally,
three participants (FRB:1, RW:2) were excluded from all data
analysis as they reported use of antibiotics during screening
and/or intervention period, which was not allowed according to
the study protocol.
In total, 158 completed the study and were included in the
analysis of the results (Table 2). Some participants were not fasted
at the examinations (one in FRB at baseline, 3 in RW at week
6), and their data was therefore not included in the analysis of
outcomes that could be sensitive to fasting status. In total, 125
returned for the follow-up visit at week 24, however one without
having a blood sample taken. Additionally, 17 participants (FRB:
11, RW: 6) were not fasted at and their data was therefore not
included in the reposted results.
Compliance, assessed by plasma AR concentrations (Table 3),
indicated poor compliance in the FRB group and compliance
apparently dropped after 6 weeks of intervention. The
compliance in the RW group is difficult to determine using
AR, since both the background diet and the refined intervention
are expected to lead to low plasma AR concentrations.
Body weight and body fat remained stable throughout
the intervention for all participants, with no differences
between groups (Table 4). The assessment of body fat
percentage using BIA was validated against body fat percentage
measured by DEXA in a subgroup of participants. The
fat percentages measured by the two methods were well
correlated (Pearson’s correlation coefficient ≥ 0.84, p > 0.001,
Supplementary Figure 1 in additional file 1), suggesting that use
of BIA for body fat was an acceptable tool in this population.
Bacterial Load- the Primary Outcome
There was no overall difference of bacterial load assessed by
13C-UBT between groups when comparing data from completers
after 12 weeks of intervention (Figure 2). When stratifying the
analyses for overweight and normal weight participants, we
TABLE 3 | Plasma total alkylresorcinol concentration and the C17:0/C21:0
alkylresorcinol ratio.
Base-line Week 6 Week 12
Total alkylresorcinol (nmol/L)a
FRB (n = 77/80/78) 2.8 (2.7) 28.0 (81.6) 16.1 (56.9)
RW (n = 79/74/79) 2.5 (3.7) 4.1 (4.7) 3.7 (4.4)
C17:0/C21:0a
FRB (n = 13/72/62)b 0.10 (0.14) 0.67 (0.52) 0.56 (0.53)
RW (n = 19/30/17)b 0.05 (0.03) 0.11 (0.31) 0.08 (0.06)
aValues are median (interquartile range).
bC17:0 was below the detection limit in many participants, which is indicative of little or
no rye intake.
found a higher bacterial load among overweight participants
consuming RW, compared to FRB, after 12 weeks of intervention
suggesting an adverse effect of RW (Figure 2).
Bacterial load at baseline differed between overweight
and normal weight participants (mean DOB was 14.4‰
in overweight participants and 22.2‰ in normal weight
participants, p= 0.01).
Serology
Overall, there were no consistent pattern in changes in the
proportion of participants who were measured positive for
virulence factor during the intervention across the two treatment
groups (Supplementary Table 1 in additional file 1). After
12 weeks of intervention anti-UreA decreased in participants
consuming FRB (73 vs. 68%, p < 0.05) but remained stable in
participants consuming RW. Anti-CagA increased in a subgroup
on normal weight participants consuming RW (59 vs. 79%, p <
0.05) but remained stable across other subgroups. There was no
change in the fraction of participants measured positive for anti-
VacA and anti-UreB during the 12 week intervention. At follow
up (week 24), the proportion of participants measured positive
for anti-CagA (65 vs. 46%, p < 0.05), anti-VacA (54 vs. 39%, p
< 0.05), anti-UreA (70 vs. 53%, p < 0.05) and anti-UreB (91
vs. 75%, p < 0.05) was reduced in the RW group, compared
to baseline, whereas the number of positive subjects in the FRB
group had only reduced for anti-UreA (87 vs. 65%, p < 0.05)
(Supplementary Table 2 in additional file 1).
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TABLE 4 | Effects on anthropometrics and clinical outcomes.
Week 0 Week 6 Week 12 1 Between groups, week 6 1 Between groups, week 12
Model 1 Model 2 Model 1 Model 2
Body weight (kg)
FRB 64.2 ± 13.3 64.4 ± 13.4 64.4 ± 13.6 0.610 0.587 0.696 0.635
RW 63.0 ± 14.3 62.6 ± 14.6 62.6 ± 14.4
Body fat (%)
FRB 30.8 ± 5.9 30.3 ± 6.2 30.0 ± 5.4 0.600 0.529 0.719 0.692
RW 31.5 ± 5.1 30.8 ± 5.9 30.5 ± 5.5
Triglycerides (mmol/L)






0.685 0.821 0.207 0.162







FRB 5.50 ± 0.86 5.54 ± 0.57 5.40 ± 0.76 0.817 0.733 0.605 0.475
RW 5.74 ± 0.98 5.64 ± 0.83 5.58 ± 0.90
Insulin (pmol/L)






0.220 0.200 0.621 0.830













0.420 0.431 0.336 0.516













0.250 0.241 0.765 0.999







FRB 5.50 ± 0.39 5.77 ± 0.39 5.78 ± 0.36 0.112 0.154 0.159 0.141
RW 5.57 ± 0.59 5.85 ± 0.53 5.87 ± 0.53
Apolipoprotein A (g/L)
FRB 1.38 ± 0.23 1.36 ± 0.22 1.35 ± 0.20 0.619 0.463 0.377 0.518
RW 1.36 ± 0.22 1.34 ± 0.23 1.36 ± 0.23
Apolipoprotein B (g/L)
FRB 1.13 ± 0.28 1.17 ± 0.28 1.15 ± 0.28 0.358 0.336 0.088 0.102
RW 1.13 ± 0.24 1.20 ± 0.20 1.22 ± 0.26
Apolipoprotein A/Apolipoprotein B
FRB 1.29 ± 0.36 1.25 ± 0.44 1.24 ± 0.37 0.175 0.109 0.244 0.203
RW 1.26 ± 0.31 1.15 ± 0.27 1.17 ± 0.36
Apolipoprotein E (g/L)
FRB 33.08 ± 5.75 33.18 ± 5.67 33.55 ± 5.69 0.514 0.465 0.485 0.347
RW 33.78 ± 5.43 33.13 ± 5.47 33.6 ± 5.27
Lipoprotein (a) (mg/L)






0.457 0.371 0.643 0.499
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TABLE 4 | Continued
Week 0 Week 6 Week 12 1 Between groups, week 6 1 Between groups, week 12
Model 1 Model 2 Model 1 Model 2
Zonulin (pg/ml)






0.954 0.847 0.639 0.727






Number of participants, when deviating from 80/78 (FRB/RW). Body weight: wk6 = 80/74, wk12 = 79/78, body fat %: wk0 = 78/77, wk12 = 79/78, insulin: wk12 = 79/77, C-peptide:
wk12 = 79/76, HOMA-IR: wk12 = 79/77, lipoprotein (a): wk6 = 77/74, wk6 = 77/74, wk12 = 78/78, zonulin: wk6 = 78/75, wk12 = 79/78.
All data is mean ± SD (median).
HOMA-IR, homeostasis model assessment insulin resistance; HbA1C, hemoglobin A1c.
n: FRB = 80, RW = 78 unless otherwise stated.
Statistically significant differences are indicated by *p < 0.05.
FIGURE 2 | Bacterial load measured 13C-urea breath test at base-line, after 6 and 12 weeks of intervention and 12 weeks post intervention (week 24) in the
fermented rye bran (FRB) and in the refined wheat (RW) group among all participants (A) and across normal weight participants (B) and overweight participants
(C). Data is mean ± SEM. DOB, delta-over-baseline. Statistically significant differences are indicated by *p < 0.05.
Glucose Metabolism and Insulin Sensitivity
We found no statistically significant difference between
interventions in any markers of glucose metabolism or insulin
sensitivity (Table 4) for all or in any of the subgroups stratified
for weight (Supplementary Tables 3, 4 in additional file 1).
Blood Lipids
No difference in TC or HDL-C was found between the
two treatments or within groups, overall or for normal or
overweighed participants separately, at base line (Figure 3).
However, LDL-C was lower in the group consuming FRB,
compared to the RW group after 12 weeks of intervention (2.79
± 0.77 vs. 3.01 ± 0.71, p = 0.007 in model 1, p = 0.011 in
model 2) (Figure 3). The effect had disappeared at the follow-up
visit at week 24, when participants consumed their habitual diet
(Supplementary Table 5 in additional file 1). Weight stratified
analyses showed that the difference in LDL-C was mainly found
among normal weight participants, but not among overweight
participants, though baseline concentration were similar among
the two weight groups (Supplementary Figures 3, 4 in additional
file 1).
Biomarkers of Inflammation and Leaky Gut
Hs-CRP was significantly lower in participants consuming FRB
instead of RW after 12 weeks of intervention (Figure 4). This
effect was found among overweight, but not normal weight
participants (Supplementary Tables 3, 4 in additional file 1).
No differences in zonulin concentrations were found between
groups, but the zonulin concentration increased in both groups
during the intervention compared to base-line (Table 4). At
the week 24 follow-up visit the zonulin concentration was
significantly higher in the RW group, compared to FRB group,
but the concentration had increased in both groups during the
follow-up period (Supplementary Table 5 in additional file 1).
DISCUSSION
In the present study we investigated and found no effect of a
12-week dietary intervention with FRB vs. RW on H. pylori
bacterial load, measured by 13C-UBT according to per-protocol
analysis. This was supported with data showing no difference in
measured virulence factors, which remained stable throughout
the intervention and showed no difference between diets. In
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FIGURE 3 | Plasma total cholesterol, low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol at base-line, after 6 and 12 weeks of
intervention and 12 weeks post intervention (week 24) in the fermented rye bran (FRB) and in the refined wheat (RW) group among all completed cases. Data is mean
± SEM. Statistically significant differences are indicated by *p < 0.05.
FIGURE 4 | Serum high-sensitive C-reactive protein (hs-CRP) at base-line,
after 6 and 12 weeks of intervention and 12 weeks post intervention (week 24)
in the fermented rye bran (FRB) and in the refined wheat (RW) group among all
completed cases. Observations ≥1 mg/dL were removed (n = 6 in FRB and n
= 5 in RW, 1.9% of all observations). Data is mean ± SEM. Statistically
significant differences are indicated by *p < 0.05.
contrast, LDL-C and hs-CRP were lower after 12 weeks of FRB
vs. RW consumption suggesting beneficial effects of high fiber rye
consumption on important cardiometabolic risk markers.
Effects on H. pylori Bacterial Load
The lack of an apparent effect on bacterial load indicated by
13C-UBT after dietary treatments is difficult to interpret but
was supported by the overall no effects on H. pylori virulence
factors, which altogether suggest no effect on H. pylori infection.
The underlying hypothesis of using UBT was that reduction of
bacterial load may have beneficial effects on H. pylori infection
and that fermented rye bran could reduce the bacterial load
through inhibition of adherence of H. pylori at the stomach
mucosa. We assumed that 13C-UBT can be used to assess and
monitor the severity ofH. pylori infection in a longitudinal study
setting rather than just determine whether a subject is positive
or negative for H. pylori. The clinical use is primarily aimed
toward determine whether a subject is positive or negative for
H. pylori, rather than tracking the severity of the infection (49).
However, some studies have shown cross-sectional associations
between UBT results and severity of infection, assessed by
endoscopic examinations and biopsies, which could indicate that
UBT can be used to estimate the severity of H. pylori infection
(50–52). On the contrary, other studies have not been able to
show this association (53, 54), and it remains to be proven
whether UBT can be used to detect changes in infections in
longitudinal design such as the present study. The absence of
the validation of UBT to track infection rate over time is an
important weakness of the present study which may explain
the lack of difference between the treatment groups. UBT test
result has been shown to differ according to factors such as age
and gender (55), as well as the use of antibiotics and proton
pump inhibitors, gastric pH, bleeding in the gastrointestinal
tract, gastric emptying rate and food consumption prior to the
test, and the matrix in which the urea tablet is consumed (14,
15). We have attempted to control these factors by excluding
participants that did not comply with fasting procedures, had
gastric ulcers or reported use of drugs that could have affected
the results. Indeed, the bacterial load was found to be higher in a
subgroup of overweight participants consuming RW, compared
to overweight participants consuming FRB, after 12 weeks of
intervention, however there were no difference between groups
when assessing the entire study population. Furthermore, the
difference between interventions among overweight participants
appears to be mainly due to an adverse effect of RW, rather than
a positive effect of FRB, on bacterial load and therefore does
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not support an effect of the tested FRB products on H. pylori
infection. Few dietary interventions targeting H. pylori infection
have been conducted and it is therefore difficult evaluate whether
12 weeks is a sufficient time-frame to evaluate the potential
of a dietary intervention to affect H. pylori infection. Valid
evaluation of treatment effect at 4–6 weeks after pharmaceutical
eradication of H. pylori infection have been shown for 13C-UBT
readouts (49). Treatment with probiotics in time range of 4–6 has
likewise been shown to reduce UBT readouts, despite probiotics
only showing modest potential for eradication of H. pylori (12).
However, it has not been established how fast H. pylori infection
will respond to a dietary intervention such as the one in the
current study.
Analysis of virulence factor antibodies is less sensitive to the
factors mentioned above, however antibodies have been shown
to persist more than 1 year after eradication of H. pylori and
may not allow distinction between past and present infection
in the relatively short timeframe of the present study and is
not recommended for monitoring of H. pylori infection (15,
56, 57). Inclusion of endoscopic examinations, either alone
or in combination with 13C-UBT, would likely have provided
a stronger measure of the bacterial load and the severity of
H. pylori infection. However, due to the invasive nature of
endoscopic examination it was not possible in the context of
this study.
Interestingly, 13C-UBT values at baseline were higher
among normal weight participants, compared to overweight
participants, which could indicate that the bacterial load was
higher among normal weight participants. This is in line with
the findings of Eisdorfer et al. who found an inverse association
between DOB values and BMI in a cross sectional study of
76,000H. pylori infected participants (55). Furthermore, increase
in BMI following eradication therapy has been observed in
some studies (58, 59), as well as an inverse association between
the hunger inducing hormone ghrelin and H. pylori infection
(60, 61). On the contrary, observational studies have shown
that obesity constitutes a risk factor for H. pylori infection (44,
45, 62). A recent cohort study showed that H. pylori infection
increased the risk of gastric cancer in participants with BMI
< 25 kg/m2, whereas infection was not associated with cancer
risk in participants with BMI ≥ 25 kg/m2 (63) and it could
be speculated that the seemingly protective effect of overweight
on gastric cancer risk could be mediated through less severe H.
pylori infection. However, the association betweenH. pylori, body
weight and underlying mechanisms warrants further research
before conclusions can be made regarding a link between H.
pylori, body weight and disease development.
Effects on Cardiometabolic Risk Factors
A significant reduction in LDL-C was found after 12 weeks of
FRB compared with RW and the effect size (6%) was in the
similar range to what has been achieved in studies investigating
the effect of oat β-glucan (64). At the follow up examination in
week 24, the difference in LDL-C observed after 12 weeks had
disappeared, which strongly support the cholesterol lowering was
a result of the FRB treatment. Wholegrain rye has previously
been shown to reduce LDL-C (38, 65, 66), however few studies
have investigated the effect of wholegrain rye specifically, but
rather investigated mixtures of wholegrains or wholegrain wheat,
hence more studies investigating the effect of rye is needed to
confirm the effect (67). The cholesterol lowering effect of oats
has been attributed to the high content of viscous fibers, and it
may be that the cholesterol lowering effect of rye is caused by
soluble arabinoxylans (37, 64, 68). It has been shown that about
80% of the variation in viscosity of water soluble dietary fiber in
wholegrain rye flour is due to water soluble arabinoxylan (69).
In contrast to wheat, the water soluble arabinoxylans in rye are
more resistant to xylanase activity, and therefore the viscosity is
retained to a larger extent throughout different food processes
(70). Intake of rye, compared to wheat, has been shown to cause
significantly higher viscosity of ileal digesta in pigs (71). Based on
this, we hypothesize that wholegrain rye may lower LDL-C due
to increased viscosity formed by its water soluble arabinoxylans,
in analogy to what has been found for beta-glucans from oats and
barley (72).
Wholegrain consumption has been linked to reductions
in low-grade systemic inflammation, but the evidence from
interventions is limited and has produced conflicting results and
few studies have been conducted solely on rye (73–76). One of
the mechanisms suggested to be involved in the link between the
intake of wholegrain or other fiber- rich foods and inflammation
is reductions in gut permeability (77). However, we found no
effect of the intervention diet on zonulin, a biomarker of gut
permeability. Nevertheless, this is in line with results from a
recent study that also found reduced low grade inflammation
but no effects on gut permeability following a intervention
comparing mixed wholegrain with mixed refined grain (30),
suggesting that other mechanisms could be involved. It should
be noted that the difference between interventions found in the
present study appears to be driven mainly by an increase in
hs-CRP concentration in the RW groups, indicating an adverse
effect of the RW diet rather than a positive effect of the FRB
diet. Consumption of refined cereals has been associated with
higher concentration of inflammatory markers in observational
studies (78), and it is possible that the introduction of a relatively
large amount of refined wheat in a population not accustomed
to consumption of refined wheat has caused the increase
in hs-CRP.
The increase in systemic zonulin seen in both of the
intervention groupsmight be an effect the protein present in both
of the diets. It has previously been shown that intestinal exposure
to gliadin upregulates zonulin expression (79).
Previous intervention studies with high-fiber rye has mainly
been conducted in northern Europe, where rye is habitually
consumed (67). The present study is, to our knowledge, the
first study to investigate metabolic effects of high-fiber rye
food consumption in a population with little or no rye in the
habitual diet. While this has provided the opportunity to test
the effect of rye without the influence of a background diet
rich in rye, this is likely the reason for the apparently lower
compliance than what could have been expected in a population
more familiar with the taste of rye, by assessment of plasma
AR concentration profiles after intervention (39, 80). The daily
amount of intervention products was high, especially considering
that the study population were not accustomed to consuming this
type of products. However, results from a pilot study indicated
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that high amounts of intervention foods were required to reach
the desired effect, and the participants in the pilot study showed
markedly better compliance than the participants of the present
study. Nevertheless, the clear trend of a group difference in risk
markers during the intervention and absence of this difference
at the follow in week 24 clearly supports a causal link between
the intervention and the reduction in risk markers, despite a
lower than expected compliance. It cannot be ruled out that
the use of complete cases analysis, rather than intention to treat
analysis, may have overestimated the effect of the intervention
and we cannot rule out that some bias was introduced due
to this approach. However, as complete cases analysis was the
defined analysis strategy for the study based on the design and
dimensioning of the study.
CONCLUSION
In conclusion, the results of the study did not support any
effect of the fermented rye bran vs. refined wheat on H. pylori
infection. However, we cannot rule out whether this is related
to the methodology used to assess the infection rate or the low
compliance. Baseline data showed lower breath test values among
overweight subjects indicating lower H. pylori bacterial loads,
which is in line with a recent cross-sectional study and warrants
further research. The FRB diet lowered LDL-C, while the RW
diet increased hs-CRP, which adds to the growing evidence
of a positive effect of rye consumption vs. refined wheat on
important risk markers of CVDs and provides an interesting tool
for prevention.
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